Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Cazzaniga ME, Cortesi L, Ferzi A et al (2016) Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat 160:501–509CrossRefPubMedPubMedCentral
2.
Cinieri S, Chan A, Altundag K et al. Final results of the randomised phase II NorCap-CA223. Trial comparing first-line all-oral versus taxane-based chemotherapy for HER2-negative MBC. Clin Breast Cancer. doi:10.​1016/​j.​clbc.​2016.​06.​014
Metadata
Title
First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer
Author
Kadri Altundag
Publication date
01-01-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4055-x

Other articles of this Issue 2/2017

Breast Cancer Research and Treatment 2/2017 Go to the issue

Epidemiology

Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample

Clinical Trial

Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial

Preclinical study

Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals

Clinical trial

Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: Ten-year audit of single centre experience

Rebuttal Letter

In reply to Kadri Altundag

Preclinical study

Endocan as a prognostic biomarker of triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits